Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 8/20 | 0.44 |
| ▸ | PPARA | Q07869 | 7/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | KRAS | P01116 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485186 | 0.87 | KMT2A (0.57) | KMT2APPARDPPARAPPARGEGFR | |
| SCHEMBL18912167 | 0.82 | GRIN2B (0.52) | KMT2APPARDPPARAPPARGGRIN2B | |
| SCHEMBL20512455 | 0.81 | ALDH1A1 (0.42) | HTR2AHTR2CKRAS | |
| SCHEMBL23519846 | 0.78 | KMT2A (0.48) | KMT2APPARDPPARAPPARGEGFR | |
| SCHEMBL3481149 | 0.78 | HTR2A (0.49) | HTR2AHTR2CKMO | |
| SCHEMBL14158772 | 0.77 | ATM (0.47) | HTR2AHTR2CKRASNTSR1 | |
| SCHEMBL16156155 | 0.76 | KMT2A (0.60) | KMT2APPARDPPARAPPARGGRIN2B | |
| SCHEMBL26683806 | 0.76 | KMT2A (0.60) | KMT2APPARDPPARAPPARGEGFR | |
| SCHEMBL418013 | 0.76 | KMT2A (0.60) | KMT2APPARDPPARAPPARGEGFR | |
| SCHEMBL1576340 | 0.76 | KMT2A (0.60) | KMT2APPARDPPARAPPARGHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394969-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | KMT2A 2171/4885PPARD 295/4885PPARA 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.